On 13 October Diederik Schrijvershof spoke about the (im)possibilities for joint purchasing of expensive prescription drugs at the congress Consequences for transparency by add-on registration in 2017, organised by MEI Zakelijke Bijeenkomsten. In his presentation (in Dutch), Diederik elaborated on the competition law aspects of the Guidelines on joint purchase of expensive prescription drugs from the Authority for Consumers and Markets. Besides the competition law aspects, Diederik also illustrated the relation between joint purchase of expensive prescription drugs and the health insurers’ duty of care. More information on the duty of care can be found in this blog (in Dutch only).
Competition | Regulation | Litigation
Maverick Advocaten speaks about joint purchase of expensive prescription drugs
19-10-2016
